Invention Grant
- Patent Title: Treatment of autoimmune and inflammatory diseases with the arsenic compounds AS2O3 and/or AS2O5 administered locally
-
Application No.: US14787002Application Date: 2014-04-25
-
Publication No.: US10438128B2Publication Date: 2019-10-08
- Inventor: Mohcine Benbijja , Pedro Bobe
- Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITE PARIS-SUD 11
- Applicant Address: FR Paris FR Orsay
- Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS),UNIVERSITE PARIS-SUD 11
- Current Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS),UNIVERSITE PARIS-SUD 11
- Current Assignee Address: FR Paris FR Orsay
- Agency: Arrigo, Lee, Guttman & Mouta-Bellum LLP
- Priority: FR1353870 20130426
- International Application: PCT/EP2014/058420 WO 20140425
- International Announcement: WO2014/174059 WO 20141030
- Main IPC: A61K33/36
- IPC: A61K33/36 ; G06N10/00 ; H01L23/00 ; H01L23/66 ; A61P17/06 ; A61P17/00 ; H01L21/56
Abstract:
The invention concerns the field of human auto-immune and/or inflammatory diseases, and more specifically the use of arsenic compounds for the preparation of drugs intended for the treatment and/or prevention of skin injuries associated with auto-immune and/or inflammatory diseases in a human subject. The invention concerns an arsenic compound As2O5 for use in the treatment and/or prevention of skin injuries associated with auto-immune and/or inflammatory diseases in a human subject, a pharmaceutical composition comprising an arsenic compound As2O5, preferably for the treatment and/or prevention of skin injuries associated with auto-immune diseases in a human subject, and products containing an arsenic compound As2O5 and an arsenic compound As2O3 as a combination product for simultaneous, separated or time-spread use in the treatment and/or prevention of skin injuries associated with auto-immune diseases in a human subject.
Public/Granted literature
Information query
